|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12Q 1/6886 | (2018.01) |
| C12Q 1/6886 | (2013.01) | ||
| A61K 31/33 | (2006.01) | ||
| C12Q2600/106 | (2013.01) | ||
| C07D 495/04 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 31/519 | (2006.01) | ||
| A61K 31/519 | (2013.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3810810 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19745306.1 |
| Date of filing the European patent application | 2019-06-18 | |
| (97) | Date of publication of the European application | 2021-04-28 |
| (45) | Date of publication and mention of the grant of the patent | 2024-03-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/JP2019/025995 |
| Date | 2019-06-18 |
| (87) | Number | WO 2019/245061 |
| Date | 2019-12-26 |
| (30) | Number | Date | Country code |
| 201862686960 P | 2018-06-19 | US |
| (72) |
OHASHI, Akihiro , JP
IWAI, Kenichi , JP
NAMBU, Tadahiro , JP
YAMANAKA, Kazunori , JP
OTAKE, Kentaro , JP
NIU, Huifeng , US
SHIN, Hyunjin , US
KOENIG, Erik Michael , US
|
| (73) |
Takeda Pharmaceutical Company Limited ,
1-1, Doshomachi 4-chome,
Chuo-ku,, Osaka-shi,
Osaka 541-0045,
JP
|
| (54) | CANCER TREATMENT METHODS BASED ON TP53 MUTATION STATUS AND HYPERMUTATION STATUS |
| CANCER TREATMENT METHODS BASED ON TP53 MUTATION STATUS AND HYPERMUTATION STATUS |